NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

PDS Biotechnology Corporation (PDSB) Stock Analysis

PDS Biotechnology Corporation (PDSB) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

PDSB

$1.24

+$0.28 (+29.10%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PDSB with… →

PDSB Key Statistics

As of Oct 21, 2026
Trading
Open
$0.99
Previous Close
$0.96
Day's Range
0.99–1.31
52-Week Range
0.20–1.79
Volume
14.93M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.17
Valuation
Market Cap
$89.87M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.64
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$34.50M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
72.47M
1-Year Return
+27.84%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
24.57M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, PDSB closed at $1.24, +27.84% over 1 year.

PDS Biotechnology Corporation (PDSB) has a market capitalization of $89.87M.

In fiscal 2025, PDSB reported revenue of $0.00.

PDSB Stock Return by Calendar Year

PDS Biotechnology Corporation (PDSB) 10-year return: what $10,000 became

1 year
$10,000 $12,784
+27.84%
5 years
$10,000 $1,071
−89.29%
10 years
$10,000 $57
−99.43%

If you had invested $10,000 in PDS Biotechnology Corporation (PDSB) 10 years ago, at the close on October 21, 2016, it would have been worth $57 at the close on October 21, 2026: −99.43% in total, −40.34% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+61.04%
2025−52.76%
2024−67.20%
2023−62.35%
2022+62.96%
2021+278.50%
2020−19.25%
2019−58.72%
2018−96.57%
2017−25.04%
2016 (partial year)+33.12%

As of October 21, 2026.

PDSB Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$34.50M—
2024$0.00−$37.61M—
2023$0.00−$42.94M—
2022$0.00−$40.85M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$31.54M−$34.50M—
2024$0.00—−$36.32M−$37.61M—
2023$0.00—−$43.05M−$42.94M—
2022$0.00—−$41.67M−$40.85M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

PDS Biotechnology Corporation (PDSB) carries a market capitalisation of $89.87M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 21 employees.

The 52-week range on file runs from $0.20 to $1.79. PDSB last closed at $1.24 on October 21, 2026. That is +$0.28 (+29.10%) against the previous close. The latest close sits 535.9% above that 52-week low.

Financial Health

In fiscal 2025, PDS Biotechnology Corporation reported revenue of $0.00. The same year closed with a net loss of $34.50M. Trailing earnings per share are −0.64.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The reported beta is 1.17. Daily returns over the trailing 10 years annualize to a volatility of 111.33%. Over the trailing twelve months the total return is +27.84%. Measured over 10 years, that is −40.34% a year compounded.

Growth & Income

The record shows no dividend for PDSB.

The strongest complete calendar year on file is 2021 at +278.50%; the weakest is 2018 at −96.57%. Of the 9 complete calendar years on file, 2 finished higher. 2026 is still running; the total return is +61.04% year to date.

Peer Comparison

PDS Biotechnology Corporation (PDSB) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
PDS Biotechnology Corporation PDSB $89.87M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. PDS Biotechnology Corporation has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About PDS Biotechnology Corporation

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein for treating acute myeloid leukemia, prostate, and breast cancer; and PDS0103 for ovarian, breast, colorectal, and lung cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate, tumor-targeting interleukin 12 immune-cytokine that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, Georgia Research Foundation, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Princeton, New Jersey.

Visit website →